Why Big Pharma sees the abortion drug legal fight as a grave business risk

by Kaelan Deese, Supreme Court Reporter

One year after the nation learned of the Supreme Court's intent to peel back federal protections for abortions via a leaked draft opinion, a new legal fight over the approval of a common abortion drug has ignited condemnation from nearly every corner of the pharmaceutical industry.

In the span of a year, the Supreme Court's overturning of Roe v. Wade has ushered in a new era of litigation in the anti-abortion movement that's being spearheaded by doctors challenging the Food and Drug Administration's "accelerated approval" regimen that allowed the 2000 approval of a common abortion drug known as mifepristone.

 […]

"Since the amount of money involved in getting a drug from point A onto a shelf or into the pharmacy is millions and millions and millions of dollars, throwing that up in the air is really problematic," political analyst John Ellis told the Washington Examiner.